Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.

UniProt release 2021_01

Published February 10, 2021

(Almost) all about that CBASS

Bacteria and archaea, like every other living organisms, must defend themselves against viral (bacteriophage or phage) attack. It is estimated that there are 1031 bacteriophages on the planet found in all habitats; sea water, animal gastrointestinal tracts, oceanic basement... A number of anti-phage defense mechanisms are known: restriction nucleases, an Argonaute-like system, CRISPR, and more are being discovered as we explore less well-known archaea and bacteria. A new phage defense mechanism has been recently discovered and is being characterized, the CBASS system (Cyclic oligonucleotide-Based Anti-phage Signalling System).

At the heart of each CBASS system is a cyclic nucleotide synthase. These belong to the cGAS/DncV-like nucleotidyltransferase family (abbreviated CD-NTase), and they make cyclic di-, tri-, and possibly even tetranucleotides. The cyclic nucleotides activate an effector protein, encoded adjacently to the CD-NTase. The effectors have a variety of activities: nucleases that degrade all DNA, including viral DNA (NucC, Cap4), an NAD+ hydrolase that presumably depletes cellular NAD+ (Cap12), phospholipases that are capable of degrading the cell membrane (CapV, CapE), and transmembrane proteins that may form pores (Cap13) have all been observed, although not all have been characterized yet.

Transforming CBASS into bacteria without a natural CBASS system protects the population against phages. The effectors lead to cell death before the phage have completed an infection cycle, thus protecting adjacent uninfected cells from infection. There are at least 4 types of CBASS systems, classified on basis of the presence or absence of ancillary genes encoded in the same locus. Type I systems have no extra genes. In type II systems, the ancillary proteins Cap2 and Cap3 are not necessary for protection against all phages, but they enlarge the range of phages against which the system is active. In type III systems, the ancillary proteins Cap6 and Cap7 control the activity of the system; Cap7 is required to activate the CD-NTase, while Cap6 prevents the Cap7-CD-NTase association. A subtype has a second Cap7-like gene called Cap8 which may act as a scaffold for complex assembly. Type IV systems are rare and so far uncharacterized. They occur mostly in Firmicutes and archaea.

At the request of Dr. Philip Kranzusch, the lead author on many of these papers, characterized CBASS proteins have been annotated. We'd like to thank Dr. Kranzusch, members of his lab, and Dr. R. Sorek for answering annotation questions. We also thank you for your interest in our knowledgebase and remind you that we are always looking for your input on our entries.

UniProtKB news

Change of the cross-references to EuPathDB: renamed to VEuPathDB

We have updated our cross-references to reflect the name change of EuPathDB into VEuPathDB, following the inclusion of genomes of invertebrate vectors of human pathogens.

Removal of the cross-references to VectorBase

Direct cross-references to VectorBase have been removed, as VectorBase is now part of the VEuPathDB resources.

Removal of the cross-references to UniCarbKB

Cross-references to UniCarbKB have been removed.

Changes to the controlled vocabulary of human diseases

New diseases:

Modified diseases:

Changes in subcellular location controlled vocabulary

New subcellular locations:

The humsavar.txt file lists all missense variants annotated in UniProtKB/Swiss-Prot human entries. It provides a variant classification which is intended for research purposes only, not for clinical and diagnostic use. Variants were previously classified into the categories Disease, Polymorphisms and Unclassified. We have renamed these categories to follow the terminology recommended by the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) (Richards et al. PubMed:25741868):

Previous categoryNew categoryDescription
DiseaseLP/Plikely pathogenic or pathogenic
PolymorphismLB/Blikely benign or benign
UnclassifiedUSuncertain significance

Previous format:

Main      Swiss-Prot             AA             Type of
gene name AC         FTId        change         variant       dbSNP          Disease name
_________ __________ ___________ ______________ _____________ ______________ _____________________
CC2D2A    Q9P2K1     VAR_075698  p.Trp1182Arg   Disease       rs386833755    Joubert syndrome 9 (JBTS9) [MIM:612285]
CC2D2A    Q9P2K1     VAR_076881  p.Ser117Arg    Unclassified  rs186264635    Joubert syndrome 9 (JBTS9) [MIM:612285]
CC2D2A    Q9P2K1     VAR_076882  p.Lys507Glu    Polymorphism  rs144439937    Joubert syndrome 9 (JBTS9) [MIM:612285]

New format:

Main      Swiss-Prot             AA             Variant
gene name AC         FTId        change         category dbSNP          Disease name
_________ __________ ___________ ______________ ________ ______________ _____________________
CC2D2A    Q9P2K1     VAR_075698  p.Trp1182Arg   LP/P     rs386833755    Joubert syndrome 9 (JBTS9) [MIM:612285]
CC2D2A    Q9P2K1     VAR_076881  p.Ser117Arg    US       rs186264635    Joubert syndrome 9 (JBTS9) [MIM:612285]
CC2D2A    Q9P2K1     VAR_076882  p.Lys507Glu    LB/B     rs144439937    Joubert syndrome 9 (JBTS9) [MIM:612285]

Also in line with the ACMG/AMP guidelines, we have at the same time deprecated the keyword "Polymorphism" and renamed the keyword "Disease mutation" to "Disease variant". This was done because the terms 'polymorphism' and 'mutation', which have been widely used, often lead to confusion due to incorrect assumptions of pathogenic and benign effects, respectively.

Entries with variant annotations can be retrieved on the UniProt website with the query annotation:(type:variant).

UniProt FTP and website news

Changes to the FTP repository for reference proteomes

We currently distribute the UniProt reference proteomes on our FTP site in four taxonomic division folders (Archaea, Bacteria, Eukaryota and Viruses) and provide, for each proteome, its sequences in FASTA format and mappings from UniProt identifiers and gene names to those found in other databases. Starting from this release, we also publish the full protein records for a proteome in the UniProtKB text and XML format, and we have at the same time introduced a subfolder for each proteome that groups all its files in order to reduce the number of files in the taxonomic division folders.

Example: UP000005640

Previous FTP folder and files:

  • UP000005640_9606.fasta.gz
  • UP000005640_9606_additional.fasta.gz
  • UP000005640_9606_DNA.fasta.gz
  • UP000005640_9606_DNA.miss.gz
  • UP000005640_9606.idmapping.gz
  • UP000005640_9606.gene2acc.gz

New FTP folder and files:

  • UP000005640_9606.dat.gzUniProtKB text format
  • UP000005640_9606.xml.gzUniProtKB XML format
  • UP000005640_9606.fasta.gz
  • UP000005640_9606_additional.fasta.gz
  • UP000005640_9606_DNA.fasta.gz
  • UP000005640_9606_DNA.miss.gz
  • UP000005640_9606.idmapping.gz
  • UP000005640_9606.gene2acc.gz

Browser support change: End of support for Microsoft Internet Explorer

We have phased out support for Microsoft's Internet Explorer (IE 11), since our user base for this web browser is continuously decreasing and has significantly fallen below 1.5%. Please switch to a more recent and supported browser in order to enjoy the full functionalities of the UniProt website.

Even if you are not using IE 11, it may be a good idea to look at the list of the browsers we support and consider switching to the most recent version of your browser for the best user experience and security.

UniProt is an ELIXIR core data resource
Main funding by: National Institutes of Health

We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

Do not show this banner again